Evidence map›Paper›PMID 29302323›Full record

SynthesisJournal of global health2017

The national and subnational prevalence and burden of age-related macular degeneration in China.

Peige Song, Yuhang Du, Kit Yee Chan, Evropi Theodoratou, Igor Rudan, Global Health Epidemiology Research Group (GHERG)

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Impaired Rod-Mediated Vision is the Functional Hallmark of Ageing and Early and Intermediate Age-Related Macular Degeneration.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Peige SongCentre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Yuhang DuCentre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Kit Yee ChanCentre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Evropi TheodoratouCentre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Igor RudanCentre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Global Health Epidemiology Research Group (GHERG)Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Centre for Global Health Research · CAUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAge-related macular degeneration (AMD) is the third most common cause of blindness, and the fourth leading cause of visual impairment worldwide, but little is known about the burden of this disease in the most populous country-China. This study provides the first comprehensive estimates of the prevalence and burden of AMD in China from 1990 to 2015, with projections till 2050.

methodsIn this study, a systematic review and meta-analysis was conducted to estimate the prevalence of AMD in China. China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database (CBM-SinoMed), PubMed, Embase and Medline were searched before September 2016. Multilevel mixed-effect meta-regression was performed to define the prevalence rates of AMD and its subtypes. UN population data were used to estimate and project the number of people affected from 1990 to 2050. Based on different demographic and geographic features, the national burden of AMD in 2000 and 2010 was distributed to different regions in China.

resultsOur search returned 2016 citations, of which 25 met the inclusion criteria. The prevalence of any AMD ranged from 2.44% (95% CI = 1.85-3.22) in people aged 45-49 years to 18.98% (95% CI = 15.05-23.66) in people aged 85-89 years. Prevalence of early AMD ranged from 1.79% (95% CI = 1.05-3.02) to 10.05% (95% CI = 6.17-15.97), and, in the case of late AMD, from 0.38% (95% CI = 0.16-0.97) to 3.88% (95% CI = 1.68-9.13). In late AMD, the prevalence of geographic atrophy (GA) was 0.15% (95% CI = 0.05-0.47) in people aged 45-49 years and 1.09% (95% CI = 0.35-3.36) in those aged 85-89 years, and the prevalence of neovascular AMD (NVAMD) ranged between 0.24% (95% CI = 0.11-0.50) and 2.79% (95% CI = 1.33-5.77). The number of people with any AMD was 12.01 million (95% CI = 9.29-15.46) in 1990 and 26.65 million (95% CI = 20.62-34.27) in 2015. Within the same period, the number of people with early AMD increased from 9.44 million (95% CI = 7.74-11.15) to 20.91 million (95% CI = 17.16-24.68), and those with late AMD rose from 2.58 million (95% CI = 1.56-4.30) to 5.74 million (95% CI = 3.46-9.59). In late AMD, the number of people living with GA ranged from 0.87 million (95% CI = 0.40-1.83) in 1990 to 1.93 million (95% CI = 0.89-4.08) in 2015, and NVAMD from 1.71 million (95% CI = 1.16-2.47) to 3.81 million (95% CI = 2.57-5.51). The projected number of people with any AMD in 2020 is 31.23 million (95% CI = 24.18-40.14), increasing to 55.19 million (95% CI = 43.04-70.30) in 2050. Between different regions, the South Central owed the most AMD cases (5.50 million in 2000 and 7.52 million in 2010), whereas the North-West China the least (0.66 million in 2000 and 0.95 million in 2010).

conclusionsThe estimates in this study suggest a substantial burden of AMD in China, with the ageing process in Chinese society, this burden will be increasing in the foreseen future. Primary and secondary prevention and treatment and effective government response are urgently needed. Improved epidemiological studies are also required to better develop eye-care strategies and health services.

Indexed as

ChinaHumansMacular DegenerationPrevalence

Identifiers

PMID29302323
PMCPMC5735777
OpenAlexW2772439167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.